Scarica l'app Stockscreener
1.67
3.09%
0.05
Dopo l'orario di chiusura:
1.64
-0.03
-1.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Precedente Chiudi:
$1.62
Aprire:
$1.65
Volume 24 ore:
3.24M
Relative Volume:
0.59
Capitalizzazione di mercato:
$265.25M
Reddito:
-
Utile/perdita netta:
$-110.78M
Rapporto P/E:
-1.5607
EPS:
-1.07
Flusso di cassa netto:
$-75.59M
1 W Prestazione:
-2.34%
1M Prestazione:
-4.02%
6M Prestazione:
+15.17%
1 anno Prestazione:
-66.93%
Intervallo 1D:
$1.60
$1.67
Intervallo di 1 settimana:
$1.60
$1.78
Portata 52W:
$1.15
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Nome
Humacyte Inc
Settore
Industria
Telefono
919-313-9633
Indirizzo
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Confronta HUMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.67 | 303.38M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-27 | Iniziato | Barclays | Overweight |
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2023-12-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-14 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Iniziato | Cowen | Outperform |
| 2021-09-24 | Iniziato | Oppenheimer | Outperform |
| 2021-09-22 | Iniziato | BTIG Research | Buy |
| 2021-09-16 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Humacyte Inc Borsa (HUMA) Ultime notizie
Is Humacyte Inc. stock trading near support levels2025 Market Outlook & Low Risk Profit Maximizing Plans - newser.com
Technical analysis overview for Humacyte Inc. Equity Warrant stockCPI Data & Advanced Technical Analysis Signals - newser.com
Using data models to predict Humacyte Inc. Equity Warrant stock movementEntry Point & Free Verified High Yield Trade Plans - newser.com
Predicting Humacyte Inc. trend using moving averages2025 Investor Takeaways & Daily Technical Stock Forecast Reports - newser.com
Multi asset correlation models including Humacyte Inc. Equity Warrant2025 Fundamental Recap & Community Driven Trade Alerts - newser.com
Is Humacyte Inc. Equity Warrant stock vulnerable to regulatory risksWeekly Market Report & Long Hold Capital Preservation Tips - newser.com
Should I hold or sell Humacyte Inc. Equity Warrant stock in 2025Earnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Humacyte Inc. Equity Warrant stock ready for a breakoutQuarterly Profit Summary & High Accuracy Investment Entry Signals - newser.com
Key metrics from Humacyte Inc.’s quarterly dataShare Buyback & Daily Volume Surge Trade Alerts - newser.com
Chart overlay techniques for tracking Humacyte Inc.July 2025 Snapshot & Community Verified Trade Alerts - newser.com
What recovery options are there for Humacyte Inc. Equity Warrant2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Will Humacyte Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Risk Managed Investment Strategies - newser.com
Tick level data insight on Humacyte Inc. volatilityPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Is Humacyte Inc. Equity Warrant stock a dividend growth opportunityJuly 2025 Levels & Reliable Entry Point Alerts - newser.com
Earnings visualization tools for Humacyte Inc.July 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Will Humacyte Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Humacyte rises on Symvess sale to military treatment facility - MSN
Why Humacyte Inc. stock remains on buy listsMarket Trend Summary & High Accuracy Swing Trade Signals - newser.com
Why Humacyte Inc. Equity Warrant stock could outperform in 2025July 2025 Macro Moves & Community Verified Swing Trade Signals - newser.com
Will Humacyte Inc. Equity Warrant stock see insider buying2025 Earnings Impact & Fast Moving Trade Plans - newser.com
Historical volatility pattern of Humacyte Inc. Equity Warrant visualized2025 Buyback Activity & Target Return Focused Picks - newser.com
Tick level data insight on Humacyte Inc. Equity Warrant volatilityWatch List & Momentum Based Trading Ideas - newser.com
Using RSI to spot recovery in Humacyte Inc. Equity WarrantWeekly Investment Recap & Entry Point Confirmation Signals - newser.com
How Humacyte Inc. Equity Warrant stock performs in high volatility marketsPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Can Humacyte Inc. stock reach $100 price target2025 Bull vs Bear & Technical Pattern Based Buy Signals - newser.com
Humacyte, Inc. (HUMA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma - The Manila Times
Humacyte (NASDAQ: HUMA) says Symvess matches vein in limb trauma; 86.6% patency - Stock Titan
Market reaction to Humacyte Inc.’s recent newsWeekly Trade Review & Reliable Trade Execution Plans - newser.com
Humacyte Inc Azioni (HUMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):